We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
After whistleblowers reached their "put up or shut up" moment for producing solid evidence of Copaxone and Azilect kickbacks—and didn't, Teva says—the generics giant has urged a judge to toss the allegations.